Month: August 2021

Revenues Q2 of $819 million. Gross margin Q2 of 28.0%. Operating margin Q2 of 15.3%. EPS Q2 of $0.64; adjusted EPS of $0.61. Free Cash for the trailing 12 months Q2 of $230 million. Guidance Q3 2021 for revenues of $810 to $850 million and at a gross margin of 28.3% plus/minus 50 basis points at Q2 exchange rates.MALVERN, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive components, today announced its results for the fiscal quarter and six fiscal months ended July 3, 2021. Revenues for the fiscal quarter ended July 3, 2021 were $819.1 million, compared to $764.6 million for the fiscal quarter ended April 3, 2021, and $581.7 million for the fiscal quarter ended July 4, 2020. Net earnings attributable to Vishay...

The Hawthorne Collective to Invest $150 million in Canadian-based RIV Capital MARYSVILLE, Ohio, Aug. 10, 2021 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG) announced today the creation of a newly formed subsidiary, The Hawthorne Collective, which will focus on strategic minority investments in areas of the cannabis industry not currently pursued by The Hawthorne Gardening Company. To that end, The Hawthorne Collective will provide a $150 million convertible loan to Toronto-based RIV Capital (TSX: RIV) (OTC: CNPOF), a cannabis investment and acquisition firm currently listed on the Toronto Stock Exchange. “The addition of The Hawthorne Collective into our portfolio allows us to explore and pursue new opportunities in an industry that is poised for significant growth in the years ahead,” said Jim Hagedorn, chairman...

Revenue is up 49% year-over-year and 27% sequentially with a return to Non-GAAP profitability PETAH TIKVA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the second quarter of 2021. Second Quarter Financial HighlightsRevenues of $56.9 million, a 49% increase from $38.3 million in Q2 2020 and up 27% from $44.7 million in the previous quarter. GAAP operating loss of $0.3 million, an improvement compared with an operating loss of $3.5 million in Q2 2020 and an operating loss of $3.7 million in Q1 2021. Non-GAAP operating income of $0.2 million, compared with an operating loss of $2.6 million in Q2 2020 and an operating loss of $3.8 million in the previous quarter. GAAP...

An Emerging Markets Sponsored Commentary ORLANDO, Fla, Aug. 10, 2021 (GLOBE NEWSWIRE) — We’re pleased today to introduce a new profiled company to our roster of high-quality stories with Consolidated Uranium Inc. (“CUR“) (TSXV: CUR) (OTCQB: CURUF), a well-financed international Uranium company with a strategy of consolidating and advancing undervalued uranium projects around the globe.  Most readers are acquainted with the appeal of Uranium, often colloquially referred to as ‘yellowcake.’ For some, the acquaintance may be in international security matters due to the incredible power of uranium in a wide variety of applications. When the wrong people/governments want it, it makes the news. Think Iran. But the true importance of Uranium is in the delivery of highly efficient, low carbon, base load power to the masses....

ANN ARBOR, Mich., Aug. 10, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today the expansion of its development team with the addition of a new senior scientist. Dr. Jimi Miller joined the Kraig Labs team in July and has hit the ground running, bringing new ideas and excitement to the research team. In his first few weeks, Dr. Miller has made significant contributions in advancing the commercialization of the Company’s new lines of nearly pure spider silk. He has reinvigorated the Kraig Labs R&D team with new ideas and methods for the development and rapid commercialization of next-generation materials. Dr. Miller joins the Kraig Labs team after receiving his Ph.D. in Molecular Biophysics and Biochemistry...

Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development program Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021 Continued progress advancing development programs, with clinical data across multiple programs anticipated in 2022 SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported financial results for the second quarter ended June 30, 2021 and provided a business update. “The Finch team has made tremendous progress executing on our clinical...

Continued record sales of higher-margin products in all channels drives 29% gross margin Fulfilled record purchase orders from every province, focusing on top-performing products resulting in a 159% increase in adult-use sales YOY and a 55% increase in Q2 market share Management to host conference call today at 10:00 a.m. Eastern TimeTORONTO, Aug. 10, 2021 (GLOBE NEWSWIRE) —  Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG) (OTCQX:WDDMF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products and brands, announced today its financial results for the three and six months ended June 30, 2021. The Company recorded second quarter 2021 total revenue of $13.8 million and net revenue of $10.6 million, a total revenue increase of 92% and net revenue increase of 81% year-over-year...

Revenue Increases 118% Year-Over-YearSecond quarter revenue increased 118% year-over-year to $81.7 million, net of $6.6 million attributed to the non-cash impact of warrantsSecond quarter GAAP operating profit of $6.1 million; Non-GAAP operating profit of $10.2 million, net of $6.6 million attributed to the non-cash impact of warrantsAll geographic regions posted significant year-over-year and sequential growth; Americas and EMEA regions revenue more than doubled year-over-yearSuccessfully completed beta testing and began shipments of Atlas Max; Very strong order backlog and positive customer feedback on increased productivity, unique XDi capabilities, and unparalleled print quality and durabilityVisibility, pipeline and confidence for the remainder of year and into next year have never been strongerAnnounced acquisition of...

Announces entry into acquisition via merger agreement with Zebra Medical Vision LTD. and binding letter of intent with USARAD Holdings Inc. to create a globally connected end-to-end radiology solution and population health platform Chairman and Chief Executive Officer, Ran Poliakine, will continue his role as Executive Chairman; Erez Meltzer, current Board member, will become the CEO in January 2022 Reports progress towards global supply chain development Ended the second quarter with cash and marketable securities of $193.4 million Management to host conference call and webcast today, August 10, at 8:30AM ET Management to host public streaming event on August 16, at 08:30AM ET NEVE ILAN, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology...

ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indications TCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof-of-concept for second TCER® molecule IMA402 Cash and cash equivalents as well as Other financial assets of $229.1 million1(€192.8 million) as of June 30, 2021, funding company operations into 2023Tuebingen, Germany and Houston, TX, August 10, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting...